Download
Download by
Scanning QR Code
Download app
Download app
Company Overview
Sihuan Pharmaceutical holding Group Co., Ltd. is a Hong Kong investment holding company engaged in pharmaceutical business. The company is mainly engaged in drug research and development, manufacturing and sales in China. Its products cover cardio-cerebrovascular, central nervous system, metabolism, tumor and anti-infection fields. Its products include cardio-cerebrovascular products such as Klingo, Agili and Odime, as well as non-cardio-cerebrovascular products such as Renao, metronidazole and roxatidine.
CEO: Fengsheng Che
Market: Hong Kong motherboard
Futu Hot List
HKUSCN
Trade HeatSearch HeatNews Heat
SymbolLatest price%Chg

Loading...

Watchlist
Futubull > Quotes > 00460 SIHUAN PHARM > Company Profile
00460 SIHUAN PHARM
1.490+0.030+2.05%
Symbol
00460
Company Name
SIHUAN PHARM
ISIN
BMG8162K1137
Listing Date
10/28/2010
Establishment Date
04/26/2006
Registration
Bermuda
Chairman
Fengsheng Che
Secretary
Yaozhong\mominghui Cai
Audit Institution
Ernst & Young accounting firm
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Clarendon House 2 Church Street P.O. Box HM1022 Hamilton HM DX Bermuda
Head Office and Principal Place of Business
Room 4309, office building, convention plaza, 1 harbour road, Wanchai, Hong Kong
Fiscal Year Ends
12-31
Employees
4223
Market
Hong Kong motherboard
Phone
86(010) - 85867669
Fax
86(010) - 85867669 - 100
Business
Sihuan Pharmaceutical holding Group Co., Ltd. is a Hong Kong investment holding company engaged in pharmaceutical business. The company is mainly engaged in drug research and development, manufacturing and sales in China. Its products cover cardio-cerebrovascular, central nervous system, metabolism, tumor and anti-infection fields. Its products include cardio-cerebrovascular products such as Klingo, Agili and Odime, as well as non-cardio-cerebrovascular products such as Renao, metronidazole and roxatidine.
Profile
Sihuan Pharmaceutical Holdings Group Limited ("Sihuan Pharmaceutical" or "the Company", together with its subsidiaries "the Group") (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Stock Exchange of Hong Kong Limited in 2010. It is an innovation-led, innovation-driven, imitation-driven, independent and leading technology platform for independent production, research and development ("R & D"). With a rich global product pipeline and mature excellent sales system of international pharmaceutical enterprises. Sihuan Medicine focuses on tumor, metabolic diseases, medical beauty, anti-infection, digestive system, cardio-cerebrovascular and other high-growth treatment areas, with independent innovation research and development and incubation of high-growth new business two-wheel drive strategy, to build China's leading medical beauty and biomedical enterprises.
Back to the Top